BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 23149464)

  • 1. Patient and tumor characteristics associated with breast cancer recurrence after complete pathological response to neoadjuvant chemotherapy.
    Ju NR; Jeffe DB; Keune J; Aft R
    Breast Cancer Res Treat; 2013 Jan; 137(1):195-201. PubMed ID: 23149464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy.
    Straver ME; Rutgers EJ; Rodenhuis S; Linn SC; Loo CE; Wesseling J; Russell NS; Oldenburg HS; Antonini N; Vrancken Peeters MT
    Ann Surg Oncol; 2010 Sep; 17(9):2411-8. PubMed ID: 20373039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.
    Sánchez-Muñoz A; Plata-Fernández YM; Fernández M; Jaén-Morago A; Fernández-Navarro M; de la Torre-Cabrera C; Ramirez-Tortosa C; Lomas-Garrido M; Llácer C; Navarro-Perez V; Alba-Conejo E; Sánchez-Rovira P
    Clin Breast Cancer; 2013 Apr; 13(2):146-52. PubMed ID: 23318089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
    Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
    J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
    Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
    Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
    Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
    Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.
    De La Cruz LM; Harhay MO; Zhang P; Ugras S
    Ann Surg Oncol; 2018 Nov; 25(12):3535-3540. PubMed ID: 29981025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response.
    Fisher CS; Ma CX; Gillanders WE; Aft RL; Eberlein TJ; Gao F; Margenthaler JA
    Ann Surg Oncol; 2012 Jan; 19(1):253-8. PubMed ID: 21725686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stratifying the outcome after neoadjuvant treatment using pathological response classification by the Japanese Breast Cancer Society.
    Mukai H; Arihiro K; Shimizu C; Masuda N; Miyagi Y; Yamaguchi T; Yoshida T
    Breast Cancer; 2016 Jan; 23(1):73-77. PubMed ID: 26423822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer.
    Le Tourneau C; Dettwiler S; Beuzeboc P; Alran S; Laurence V; Pierga JY; Fréneaux P; Sigal-Zafrani B; Diéras V; Vincent-Salomon A
    Am J Clin Oncol; 2012 Jun; 35(3):242-6. PubMed ID: 21358298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
    Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of neoadjuvant chemotherapy on histologic grade and expression of biological markers in breast cancer].
    Yin HF; Wang YH; Qin XQ; Zhang H; Li T; Ye JM; Liu YH
    Zhonghua Zhong Liu Za Zhi; 2009 Nov; 31(11):858-62. PubMed ID: 20137353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancers.
    Enomoto Y; Morimoto T; Nishimukai A; Higuchi T; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Nomura T; Takeda M; Watanabe T; Hirota S; Miyoshi Y
    Int J Clin Oncol; 2016 Apr; 21(2):254-261. PubMed ID: 26338270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are we Overtreating Hormone Receptor Positive Breast Cancer with Neoadjuvant Chemotherapy? Role of OncotypeDx
    Kantor O; Barrera E; Kopkash K; Pesce C; Barrera E; Winchester DJ; Yao K
    Ann Surg Oncol; 2019 Oct; 26(10):3232-3239. PubMed ID: 31342379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Margins in Breast-Conserving Surgery After Neoadjuvant Therapy.
    Choi J; Laws A; Hu J; Barry W; Golshan M; King T
    Ann Surg Oncol; 2018 Nov; 25(12):3541-3547. PubMed ID: 30128902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor Biology Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients Presenting with Locally Advanced Breast Cancer.
    Gentile LF; Plitas G; Zabor EC; Stempel M; Morrow M; Barrio AV
    Ann Surg Oncol; 2017 Dec; 24(13):3896-3902. PubMed ID: 28916978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
    Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
    Prat A; Saura C; Pascual T; Hernando C; Muñoz M; Paré L; González Farré B; Fernández PL; Galván P; Chic N; González Farré X; Oliveira M; Gil-Gil M; Arumi M; Ferrer N; Montaño A; Izarzugaza Y; Llombart-Cussac A; Bratos R; González Santiago S; Martínez E; Hoyos S; Rojas B; Virizuela JA; Ortega V; López R; Céliz P; Ciruelos E; Villagrasa P; Gavilá J
    Lancet Oncol; 2020 Jan; 21(1):33-43. PubMed ID: 31838010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy.
    Rossi L; Verrico M; Tomao S; Ricci F; Fontana A; Spinelli GP; Colonna M; Vici P; Tomao F
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):105-111. PubMed ID: 31754747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined neoadjuvant chemotherapy with bevacizumab improves pathologic complete response in patients with hormone receptor negative operable or locally advanced breast cancer.
    Makhoul I; Klimberg VS; Korourian S; Henry-Tillman RS; Siegel ER; Westbrook KC; Hutchins LF
    Am J Clin Oncol; 2015 Feb; 38(1):74-9. PubMed ID: 23563210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.